DOCSLIB.ORG

Systemic Rheumatic Diseases from Biological Agents to Small Molecules

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systemic Rheumatic Diseases from Biological Agents to Small Molecules Autoimmunity Reviews 18 (2019) 583–592 Contents lists available at ScienceDirect Autoimmunity Reviews journal homepage: www.elsevier.com/locate/autrev Review Systemic rheumatic diseases: From biological agents to small molecules T ⁎ Piercarlo Sarzi-Puttinia, , Angela Ceribellia, Daniela Marottob, Alberto Batticciottoc, Fabiola Atzenid a Rheumatology Unit, ASST Fatebenefratelli-Sacco, University of Milan, Italy b Rheumatology Unit, P-Dettori Hospital, Tempio Pausania, Italy c Rheumatology Unit, Internal Medicine Department, ASST Settelaghi, Ospedale Di Circolo - Fondazione Macchi, Varese, Italy d Rheumatology Unit, University of Messina, Messina, Italy ARTICLE INFO ABSTRACT Keywords: The development of biologics and small oral molecules has recently changed the scenario of pharmacologic Biological therapies treatment of systemic rheumatic diseases and it has become a real revolution. These drugs have innovative Biosimilars mechanisms of action, based on the inhibition of specific molecular or cellular targets directly involved in Rheumatoid arthritis disease pathogenesis. Spondyloartropathies This new scenario has lead to a regular update of the management recommendations of several institutions, Psoriatic arthritis such as those for Rheumatoid Arthritis treatment that address the use of conventional and biologic therapies Small molecules Guidelines including TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, ri- Recommendations tuximab, IL-6 inhibitors (tocilizumab and sarilumab), biosimilars and small oral molecules (the JAK inhibitors tofacitinib and baricitinib). Monotherapy, combination therapy, treatment strategies (such as treat-to-target) and the targets of sustained clinical remission or low disease activity are the final goal of the guidelines for rheumatic patients management. In another condition represented by Axial Spondyloarthritis guidelines suggest to start first with non-steroidal anti-inflammatory drugs to improve lifestyle and reduce spine inflammation, but if this is not achieved in 2–4 weeks it is important to consider the use of local therapies (i.e. glucocorticoid injections) or to start biologic therapy such as TNF inhibitors and then eventually switching to another TNF inhibitor or swapping to IL-17 inhibitor. In the case of active Psoriatic Arthritis, guidelines suggest to start with non-steroidal anti-inflammatory drugs and even local glucocorticoid injections especially for oligoarthritis, then to start conventional therapies if lack of efficacy, and finally start biologics or small oral molecules inthe presence of drugs toxicity, unfavorable prognostic factors and still active arthritis. In several cases, active Psoriatic Arthritis patients develop a complex clinical condition with comorbidities such as diabetes, in- flammatory bowel disease and high risk of infections, and for this reason the American College of Rheumatology and the National Psoriasis Foundation have developed specific guidelines for their management. Biologic and new small molecules therapies are very expensive, but the availability of biosimilars offers the opportunity of reducing the treatment cost and significantly decreasing the cost of originators as well. In fact,we live in a period characterized by the need to rationalize costs of these drugs, to allow treating a higher number of patients and to maintain a homogeneous possibility of treatment choice. For these reasons, we need to follow scientific guidelines and patients' clinical conditions to choose the correct treatment, also based on theeconomic burden of therapies. Abbreviations: ANCAs, anti-neutrophil cytoplasmic antibodies; AxSpa, ankylosing spondylitis; BD, Behçet's disease; bDMARDs, biological DMARDs; CCP, cyclic citrullinated peptides; CD, Crohn's disease; cDMARDs, conventional DMARDs; CRP, C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; EMA, European Medicines Agency; ESR, erythrocyte sedimentation rate; EULAR, European League against Rheumatism; FDA, Food and Drug Administration; GRAPPA, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; JAK, Janus kinase; JAKin, JAK inhibitors; IBD, inflammatory bowel disease; i.v., intravenous; LFN, leflunomide; mAB, monoclonal antibody; MTX, methotrexate; MTX-IR, incomplete responder to MTX; NPF, National Psoriasis Foundation; NSAIDs,non- steroidal anti-inflammatory drugs; OSM, oral small molecules; PDE4, phosphodiesterase 4; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis;RCT, randomised controlled trial; ReA, reactive arthritis; RF, rheumatoid factor; s.c., subcutaneous; tsDMARDs, targeted synthetic DMARDs; SSZ, sulfasalazine; TNFα, tumour necrosis factor alpha; TNFin, TNF inhibitor; UC, ulcerative colitis; TRAPS, TNF receptor-associated periodic syndrome ⁎ Corresponding author at: Rheumatology Unit, ASST Fatebenefratelli-Sacco, University of Milan, Via GB Grassi 74, 20157 Milano, Italy. E-mail address: [email protected] (P. Sarzi-Puttini). https://doi.org/10.1016/j.autrev.2018.12.009 Received 7 December 2018; Accepted 12 December 2018 Available online 05 April 2019 1568-9972/ © 2019 Elsevier B.V. All rights reserved. P. Sarzi-Puttini, et al. Autoimmunity Reviews 18 (2019) 583–592 1. Introduction golimumab can induce the clinical and endoscopic remission of in- flammatory bowel disease (IBD), which is not true for the soluble eta- The development of biological agents and, more recently, oral small nercept [10]. molecules whose innovative mechanisms of action are based on in- It has been demonstrated that TNFin are effective and well tolerated hibiting specific molecular or cellular targets directly involved indis- in a large proportion of patients involved in RCTs, but primary and ease pathogenesis has revolutionised the pharmacological treatment of secondary failures of TNFin strategies affect 30–50% of patients treated systemic rheumatic diseases. The results of randomised clinical trials in clinical practice, particularly those with long-standing diseases [11]. (RCTs) and real-life reports from national registries have clarified many For this reason, a number of other bDMARDs has been developed and of the aspects of biological disease-modifying anti-rheumatic drugs approved for treatment in the case of the failure of anti-TNFα therapy (bDMARDs) in patients with inflammatory rheumatic disorders, in- (Fig. 1), and they will be discussed in the next paragraphs. cluding their mechanisms of action, efficacy and safety, and the pos- sibility of optimising their use in individual patients in order to ensure 1.1.2. Non-anti-TNFα biological agents for the treatment of RA personalised medicine. However, the data concerning Janus kinase In more recent years, additional biologics with different targets and (JAK) inhibitors only come from RCTs, and we still need to discover mechanisms of action have been developed for the treatment of rheu- from registries and real-life experience what their role in future treat- matic diseases (Fig. 1). ment strategies will be. Abatacept, a recombinant fusion protein that selectively modulates The therapeutic models considered in this review are rheumatoid a co-stimulatory signal necessary for T-cell activation, is currently ap- arthritis (RA), ankylosing spondyloarthritis (AxSpA), and psoriatic ar- proved in the EU for use in patients with highly active and progressive thritis (PsA). RA who have not previously received methotrexate (MTX) or who have inadequately responded to previous treatment with at least one con- 1.1. Biological therapies ventional DMARD (cDMARD) including MTX, or TNFin [12,13]. In phase III trials, beneficial effects on RA signs and symptoms, disease 1.1.1. Biological anti-TNFα agents for the treatment of RA activity, structural damage progression and physical function were seen Tumour necrosis factor alpha (TNFα) is an important host defence with both i.v. or s.c. abatacept regimens, in particular in association molecule involved in the acute phase reaction induced by inflammation with methotrexate [14]. Abatacept was also authorised for the treat- and capable of recruiting other pro-inflammatory mediators after its ment of active PsA [15] in the USA (July 2017) and by the EMA (August release [1]. It is the target of five specific inhibitors (TNFin) that have 2017) (Figs. 1 and 2). been approved since 2000 (Fig. 1): intravenously administered (i.v.) Tocilizumab is an IL-6 receptor antagonist that is approved (with infliximab, and subcutaneously administered (s.c.) adalimumab, cer- and without MTX) for the treatment of adults with moderate to severe tolizumab pegol, etanercept and golimumab [2,3]. All these molecules active RA. Extensive clinical experience with both i.v. and s.c. regimens are monoclonal antibodies (mAbs) or fragments of mAbs, while eta- has firmly established their short- and long-term efficacy and safetyin nercept is a fusion protein composed of the 2 extracellular portions of adults with early-stage or established RA [16]. In clinical trials and the the human TNF receptor 2 (p75 TNF receptor) and the Fc portion real world settings, tocilizumab leads to a rapid and sustained im- (hinge, CH2 and CH3 domains) of human IgG1 (Fig. 1)[4]. Anti-TNFα provement in clinical and radiographic outcomes and the health-related agents have proved to be safe when correctly prescribed and monitored quality of life [17]. The safety profile of tocilizumab is comparable to [5–7] and, over the last 20 years, have been approved for the treatment other immunomodulatory
Load more

Recommended publications
  • Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
    Predictive QSAR tools to aid in early process development of monoclonal antibodies John Micael Andreas Karlberg Published work submitted to Newcastle University for the degree of Doctor of Philosophy in the School of Engineering November 2019 Abstract Monoclonal antibodies (mAbs) have become one of the fastest growing markets for diagnostic and therapeutic treatments over the last 30 years with a global sales revenue around $89 billion reported in 2017. A popular framework widely used in pharmaceutical industries for designing manufacturing processes for mAbs is Quality by Design (QbD) due to providing a structured and systematic approach in investigation and screening process parameters that might influence the product quality. However, due to the large number of product quality attributes (CQAs) and process parameters that exist in an mAb process platform, extensive investigation is needed to characterise their impact on the product quality which makes the process development costly and time consuming. There is thus an urgent need for methods and tools that can be used for early risk-based selection of critical product properties and process factors to reduce the number of potential factors that have to be investigated, thereby aiding in speeding up the process development and reduce costs. In this study, a framework for predictive model development based on Quantitative Structure- Activity Relationship (QSAR) modelling was developed to link structural features and properties of mAbs to Hydrophobic Interaction Chromatography (HIC) retention times and expressed mAb yield from HEK cells. Model development was based on a structured approach for incremental model refinement and evaluation that aided in increasing model performance until becoming acceptable in accordance to the OECD guidelines for QSAR models.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Pharmaco-Immunomodulatory Therapy in COVID-19
    UC Irvine UC Irvine Previously Published Works Title Pharmaco-Immunomodulatory Therapy in COVID-19. Permalink https://escholarship.org/uc/item/9r8859hb Journal Drugs, 80(13) ISSN 0012-6667 Authors Rizk, John G Kalantar-Zadeh, Kamyar Mehra, Mandeep R et al. Publication Date 2020-09-01 DOI 10.1007/s40265-020-01367-z Peer reviewed eScholarship.org Powered by the California Digital Library University of California Drugs https://doi.org/10.1007/s40265-020-01367-z LEADING ARTICLE Pharmaco‑Immunomodulatory Therapy in COVID‑19 John G. Rizk1 · Kamyar Kalantar‑Zadeh2,3,4 · Mandeep R. Mehra5 · Carl J. Lavie6 · Youssef Rizk7 · Donald N. Forthal8,9 © Springer Nature Switzerland AG 2020 Abstract The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host infammatory response. The cytokine storm and viral evasion of cellular immune responses may play an equally important role in the pathogenesis, clinical manifestation, and outcomes of COVID-19. Sys- temic proinfammatory cytokines and biomarkers are elevated as the disease progresses towards its advanced stages, and correlate with worse chances of survival. Immune modulators have the potential to inhibit cytokines and treat the cytokine storm. A literature search using PubMed, Google Scholar, and ClinicalTrials.gov was conducted through 8 July 2020 using the search terms ‘coronavirus’, ‘immunology’, ‘cytokine storm’, ‘immunomodulators’, ‘pharmacology’, ‘severe acute respira- tory syndrome 2’, ‘SARS-CoV-2’, and ‘COVID-19’. Specifc immune modulators include anti-cytokines such as interleukin (IL)-1 and IL-6 receptor antagonists (e.g. anakinra, tocilizumab, sarilumab, siltuximab), Janus kinase (JAK) inhibitors (e.g.
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Targeting GM-CSF in Rheumatoid Arthritis A.B
    Targeting GM-CSF in rheumatoid arthritis A.B. Avci1, E. Feist2, G.R. Burmester2 1Department of Internal Medicine, ABSTRACT well-known as a haemopoietic growth Rheumatology, Akdeniz University, Granulocyte-macrophage colony-stim- factor used to treat neutropenia follow- Faculty of Medicine, Antalya, Turkey; ulating factor (GM-CSF) is well-known ing chemotherapy. It was a long-time 2Department of Rheumatology and as a haemopoietic growth factor. How- concern that targeted therapies against Clinical Immunology, Charite-University Medicine Berlin, Berlin, Germany. ever, it is also essential in regulating this cytokine could cause severe side functions of mature myeloid cells such effects such as neutropenia or pulmo- Ali Berkant Avci, MD, Assoc. Prof. Eugen Feist, PD Dr as macrophages. Preclinical studies nary alveolar proteinosis. Therefore, Gerd-Rüdiger Burmester, Prof. Dr. and observations of flares of arthritis in during the early development phase Please address correspondence to: patients following GM-CSF treatment of compounds targeting GM-CSF or Ali Berkant Avci, MD, supported its important contribution to its receptor special attention was paid Akdeniz Üniversitesi Hastanesi, the pathogenesis of rheumatoid arthritis to this potential adverse event reveal- İç Hastalıkları AD Romatoloji BD, (RA). As the most advanced compound, ing no evidence for such an associated Kampüs 07059 Konyaaltı/Antalya, mavrilimumab, a monoclonal antibody risk profile. On the other hand the so Turkey. against GM-CSF receptor, has already far available results clearly showed E-mail:[email protected] completed phase II trials with a long rapid and sustained effects on disease Received and accepted on June 29, 2016. term of follow-up period of 74 weeks.
    [Show full text]
  • WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A01N 43/00 (2006.01) A61K 31/33 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, PCT/US2016/028383 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (22) International Filing Date: PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 20 April 2016 (20.04.2016) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 62/154,426 29 April 2015 (29.04.2015) US TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: KARDIATONOS, INC. [US/US]; 4909 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Lapeer Road, Metamora, Michigan 48455 (US).
    [Show full text]
  • Meta-Analysis of Safety of Granulocyte-Macrophage Colony- Stimulating Factor in the Treatment of Rheumatoid Arthritis Rami Diab MD, Mohinder Vindhyal MD
    Meta-analysis of Safety of Granulocyte-Macrophage Colony- Stimulating Factor in the Treatment of Rheumatoid Arthritis Rami Diab MD, Mohinder Vindhyal MD Introduction and Background Results (continued) • Rheumatoid arthritis (RA) is characterized by chronic joint and systemic GM-CSF Placebo inflammation with potential for irreversible joint damage. AAE Total AAE Total • Not uncommonly, resistance to treatment and treatment failures limit adequate disease control. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoeitic growth factor and pro-inflammatory cytokine stimulating proliferation of mature myeloid cells secondarily endorsing inflammatory mediators with the potential to exacerbate RA. • GM-CSF monoclonal antibodies therefore represent an innovative treatment option in refractory RA. The purpose of this meta-analysis was to evaluate the Favors GM-CSF Favors Placebo safety profile of mavrilimumab (Mv) and namilumab (Nm), two novel GM-CSF Fig 1: Forest plot demonstrating statistically significant overall greater likelihood of Any Adverse Event (AAE) in monoclonal antibodies. Mavrilimumab (Mv) and Namilumab (Nm) treated patients combined vs. placebo Methods • PubMed through Oct 2019: Various iterations of keyword and MeSH term searches including GM-CSF Placebo “GM-CSF”, “monoclonal antibodies”, and “rheumatoid arthritis” were performed. AAE Total AAE Total • Selected studies investigated specific GM-CSF monoclonal antibodies in RA patients receiving at least two doses of the study drug and reported on any adverse events (AAEs) in at least one patient over at least six weeks as a primary endpoint. • Secondary endpoints included individual adverse events (IAEs) for each agent. Results Favors GM-CSF Favors Placebo • Eight randomized clinical trials evaluating Mv and Nm GM-CSF monoclonal Fig 2: Forest plot demonstrating statistically significant overall greater likelihood of Any Adverse Event (AAE) in antibodies in 908 subjects were included.
    [Show full text]
  • Novel Psoriasis Therapies and Patient Outcomes, Part 2: Biologic Treatments
    Novel Psoriasis Therapies and Patient Outcomes, Part 2: Biologic Treatments Meghan A. Feely, MD; Barry L. Smith, MD; Jeffrey M. Weinberg, MD Practice Points Novel biologic treatments promise exciting new therapeutic avenues for psoriasis and psoriatic arthritis (PsA). Although biologics currently in use for treatment of psoriasis and PsA are in the form of tumor necrosis factor α inhibitors, other drugs in phase 2 through phase 4 clinical trials aim to target alternative pathways underlying the pathogenesis of these disorders, including IL-12/IL-23 inhibition, IL-17 inhibition, inhibition of T-cell activation in antigen-presenting cells, regulatory T-cell activation, toll-like receptor inhibition, and granulocyte-macrophage colony-stimulating factor inhibition. New approaches to the management of psoriasis and PsA offer patientscopy hope for more targeted treat- ment regimens. not Biologic treatments have revolutionized the man- second in a 3-part series on treatments presently agement of psoriasis and psoriatic arthritis (PsA).Do in the pipeline for the management of psoriasis Anti–tumor necrosis factor (TNF) α monoclo- and PsA including topical agents, biologic treat- nal antibodies presently are approved by the ments, and systemic therapies in phase 2 through US Food and Drug Administration (FDA) for treat- phase 4 clinical trials as well as agents that are ment of these conditions. In this article, new recently FDA approved. Pivotal clinical trials, therapies that target this pathway and other steps mechanisms of action, patient outcomes, and in the pathogenesis of psoriasis and PsA are dis- pertinent safety information will be discussed for cussed, including IL-12/IL-23, IL-17, T-cell activa- each new therapy.
    [Show full text]
  • Efficacy and Safety of Namilumab, a Human Monoclonal Antibody Against Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
    Taylor et al. Arthritis Research & Therapy (2019) 21:101 https://doi.org/10.1186/s13075-019-1879-x RESEARCH ARTICLE Open Access Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte- macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial Peter C. Taylor1* , Didier Saurigny2,9, Jiri Vencovsky3, Tsutomu Takeuchi4, Tadashi Nakamura5, Galina Matsievskaia6, Barbara Hunt7, Thomas Wagner8,11, Bernard Souberbielle2,10 and for the NEXUS Study Group Abstract Background: Namilumab (AMG203), an immunoglobulin G1 monoclonal antibody that binds with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), was evaluated in a phase II randomized, double-blind, placebo-controlled study to investigate the efficacy and safety in patients with rheumatoid arthritis (RA) with an inadequate response to methotrexate (MTX-IR) or anti-tumour necrosis factor therapy (TNF-IR). Methods: Subcutaneous namilumab (20, 80, or 150 mg) or placebo was administered at baseline and weeks 2, 6, and 10 in patients on stable background methotrexate therapy who were with MTX-IR or TNF-IR. Primary endpoint was mean change from baseline in the 28-joint Disease Activity Score, C-reactive protein version (DAS28-CRP) at week 12 comparing each of the three doses of namilumab to placebo. Safety and tolerability were assessed by adverse events (AEs) and pulmonary parameters. Results were analysed using the per-protocol population. (Continued on next page) * Correspondence: [email protected] 1Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford OX3 7LD, UK Full list of author information is available at the end of the article © The Author(s).
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    INN Working Document 05.179 Update 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2013 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int ) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected] ). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html ). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]